Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

BMO Capital Maintains Outperform on Korro Bio, Maintains $120 Price Target

Author: Benzinga Newsdesk | May 15, 2024 09:02am
BMO Capital analyst Kostas Biliouris maintains Korro Bio (NASDAQ:KRRO) with a Outperform and maintains $120 price target.

Posted In: KRRO

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist